From: Steven Sinofsky < I=> Sent: Thursday, November 2, 2017 10:24 PM To: Masha Drokova Cc: Jeffrey E. Subject: Re: Greetings Masha, =br> I apologize for the delay. I was at some events in in U= where I did not have connectivity. I have worked o= a related portfolio company so I will have to be a bit abstract on the spe=ifics of this opportunity. So please excuse these brief thoughts. Als=, the only information I had was what was provided in your mail which was l=mited relative to any detailed analysis. * In gene=al the challenge with glucose measurement is the finger prick. Any device t=at relies on this will only be marginally better than any other device, whe=her or not there is software or a slightly more convenient measuring device= This is a statement about the inconvenience of a prick (and long term chal=enges) but also the medical challenges on relying on that point in time. * My sense is that going down the path of an innovation, that still h=s a prick, but requires a level of FDA approval is a difficult one to appro=ch. * This is a very crowded space. There are a lot of apps, a lo= of measuring devices, a lot of mixtures of app and measuring devices. It i= very difficult to avoid appearing as a commodity to consumers. *=While I understand there is potential to see innovation using novel approac=es to analysis of data, it is not clear to me how much better the approach c=n be for an individual with data. * The real opportunity I might s=e is around measuring glucose or some related telemetry to assist in compli=nce that is outside the scope of a finger prick and measuring glucose direc=ly. It seems like we should have some other data point upon which to apply m=chine learning. I hope this helps...any friend of Jr. is a friend of mine. On Nov 1, 2017, at 4:43 PM, Masha Droko=• &=t; wrote: Thank yo= Jeffrey. Steve, great meeting you. Would appreciate your f=edback On Nov 1, 2017, at 9:31 AM, jeffrey E. <[email protected]